ARTICLE INFO

Article Type

Original Research

Authors

Mojtahedi‎   F. (1)
Pooladi   A. (2)
Sirati‎   F. (3)
Kaihani‎   E. (1)
Akhlaghpour‎   Sh. (4)
Karimlou   M. (5)
Bagherizadeh‎   I. (6)
Fallah‎   M. (1)
Ghasemi Firouzabadi ‎   S. (1)
Behjati‎   F. (*)






(*) Genetic Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
(1) ‎Genetic Research Center‎, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
(2) ‎“Sarem Fertility & Infertility Research Center (SAFIR)” and “Sarem Cell Research Center (SCRC)”‎, Sarem Women’s Hospital, Tehran, Iran
(3) ‎Surgery Department‎, Medicine Faculty, Tehran University of Medical Sciences‎, Tehran, Iran
(4) Navid Medical Center, Tehran, Iran
(5) ‎Statistics Department‎, Medicine Faculty‎, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
(6) ‎“Sarem Cell Research Center (SCRC)” and “Medical Genetics Department”, Tehran, Iran

Correspondence


Article History

Received:  May  15, 2016
Accepted:  June 25, 2016
ePublished:  August 15, 2017

BRIEF TEXT


Breast cancer is the most common malignancy in women [1]. ... [2-4].In developing countries, the ‎incidence of breast cancer is also increasing [5].‎

‎.. [6]. Laboratory tests are one of the most important and most effective early diagnostic tools that are ‎based on the evaluation of markers in available body fluids such as peripheral blood. One of the ‎indicated markers is the radiation sensitivity of the lymphocyte.‎ Chromosomes tend to be sensitive to radiation in most cancers, such as breast cancer, a percentage of ‎colorectal cancer, or cancers of the head and neck. About 5 to 14% of the natural population is also ‎allergic to radiation. Therefore, it has been suggested that chromosomal sensitivity to radiation be ‎used as an indicator of the potential for cancer. Differences in the ability to repair DNA may cause a ‎change in radiation sensitivity among normal individuals [5].‎

The aim of this study was to evaluate the sensitivity of radiation in non-inherited breast cancer in ‎Iranian women.‎

This study is an observational-analytical study carried out using a case-control method.‎

Individuals with non-inherited breast cancer were examined at Mehrad Hospital in Tehran compared ‎with healthy people.‎

A total of 32 individuals with non-inherited breast cancer were studied. These patients did not receive ‎any treatment at the start of the study. Thirty healthy subjects were selected as control group, who had ‎no history of cancer in their first and second degree relatives. Since access to healthy volunteers who ‎had all criteria for entering the study, along with the criteria for matching on the basis of the variables, ‎were limited, in some variables, such as age at the first pregnancy, menarche age and age of ‎menopause, the two groups were identical and in Others, such as the age and the number of ‎pregnancies, this consistency was not achieved that with the help of statistical evaluations, the effect of ‎these variables was checked so that, if there was an effect on the outcome, it could be counterbalanced.‎

Before sampling, consent was taken from all the participants. 5 cc of Heparin blood was taken from all ‎the participants. Samples were left at 4 ° C for 24 hours and then cultured. In the patient group, all ‎clinical parameters such as tumor size, lymph node involvement status, estrogen receptor and ‎progesterone receptor status, status of expression of p53, HER-2 and grade stage genes were studied ‎and recorded through patient files.‎ The RPMI 1640 culture media which contained bicarbonate sodium and L-glutamine (Eurocolone Lot ‎No: ECM 0495D), penicillin-streptomycin (Eurocolone Cat No: ECB3001D), Eurocolone Lot No: ‎ECS0170D and phytohemagglutinin (GIBCO Cat No: 10576- 015) were used. According to the ‎chromosomal decomposition program using G2, irradiation was performed 72 hours after cell culture. ‎The incident beam was gamma ray with a dose of 0.4 Gy.‎ Removal of cells: Half an hour after radiation by adding calcium, the cells stopped in the metaphase ‎step [7-15]. The second step was to adjoin them with a hypothalamic solution (Hypotone). Due to this ‎proximity, the cells were bulky and the chromosomes got enough space to disperse within the ‎lymphocytes. The third stage is the stabilization of the cells. Finally, samples were prepared and ‎examined after staining. From each sample, three cultures were prepared, two of which were exposed ‎to radiation, and third culture as control culture in all conditions was similar to the other two cultures ‎except irradiation. From the irradiation cultures, a total of 50 cells were examined and from control ‎culture, also, 50 cells were removed for chromosomal counts and evaluation.‎ In the microscopic analysis of metaphyseal lymphocytes, the percentage of abnormal cells was used to ‎determine the sensitivity of the radiation. Maladaptive cells are counted based on the existence of ‎failures that cause abnormalities, chromatid and chromosome clefts (when lack of continuity in the ‎chromatid building is wider than the width of a chromatid), rearrangements (such as chromosomes ‎ring and dicentric chromosome) and the radial forms (3 radial and four radial forms) cells. When ‎discontinuity in the structure of the chromatid is less than one chromatid, chromatid and ‎chromosomal clefts are not considered as chromosomal abnormality.‎ Data were analyzed by SPSS 19 software. Parametric tests (T-test and Paired t-test) and nonparametric ‎tests (Chi-square and Fisher exact tests) were used to assess the significant difference between mean ‎sizes of variables. The evaluation of the radiation sensitivity test was performed based on the ‎characteristics of the system function or the ROC Curves 1 and performing the C-statistics. In this ‎study, in addition to calculate the borderline for each test index based on the Youden index, the ‎sensitivity and specificity of the test were determined at the critical point and the odds ratio was ‎estimated at 95% confidence interval.‎

The mean age in the affected population was 53.25 years with a range of 32-84 years and in healthy ‎subjects it was 31.33 years with a range of 18-49 years (Table 1).‎ Considering the significant difference in the age and number of pregnancy variables between the two ‎groups of patients and control, it is likely that these two variables can be considered as confounding ‎ones and this can cause the results to be skeptical, that in this respect, the necessary studies were ‎done. Since for a variable to be confounding, the existence of a relationship with both the independent ‎variable and the dependent variable or the same outcome is certain, it should be said that the two ‎variables of age and the number of pregnancies, at least with the condition of exposure to radiation ‎sensitivity, had no definable and definite association. However, statistical analysis took place in this ‎regard. Pearson and Spearman correlation test showed a lack of correlation with the results of the tests ‎and, therefore, there was no ambiguity in term of their likelihood of confusion. ‎ The distribution of breast cancer patients according to the tumor stage (according to the three-letter ‎TNM system) showed that 7 patients (23.3%) had stage I, 4 cases (13.3%), had stage Iia; 16 cases ‎‎(53.3% %) had Stage IIb, one case (3.3%) had stage IIIa and two cases (6.7%) also had stage IIIb. In ‎‎62.5%, the tumor had a moderate distinction or a score of 2. In 33.3% of the cases, the tumor had a ‎high distinction or score of 1, and only in 3.1 % of the patients, tumor had a score of 3. The presence or absence of estrogen, progesterone, p53 and HER-2 receptor was a very important part ‎of the study (Table 2).‎ The percentage of abnormal cells in both patient and control groups was significantly different in each ‎case before and after irradiation (Chart. 1, p = 0.00001).‎ Comparing this index between patient groups and the control group, the presence of abnormal cells ‎prior to irradiation showed no significant difference (p> 0.05), but after irradiation, and also the ‎difference in pre and post changes in the percentage of abnormal cells, the difference was significant ‎‎(p<0.05).‎ Statistical analysis and calculation of C index for percentage of abnormal cells in G2 stage to γ radiation ‎showed that this index can be a significant index with acceptable level of AUC (0.725) (p <0.05) that ‎can be helpful in terms of clinical and decision-making with the odd ratio (Chart 2).‎ The odds ratio at critical point of 61% was 3.818 (CI95% = 1.323-10.942), so that in those who had an ‎increase in the percentage of abnormal cells after irradiation than before irradiation it was equal to or ‎greater than 61%. The probability of being affected was more than 4 times (3.818) more than other ‎people. At the critical point of 61%, the sensitivity of this index was 65.6% and the specificity was ‎‎66.6%, which could be acceptable for a test. This test can accurately identify approximately 65.6% of ‎the patients and 66.6% of normal people can be identified as healthy with test. ‎ Irradiation caused various clefts and abnormalities in chromosomes (Figures 1 and 2).‎

‎... [16-19].In various studies, the sensitivity of radiation in patients with breast cancer has been ‎investigated [14, 15, 20-22]. In some studies, it has shown that about 40% of breast cancer patients ‎have high sensitivity to radiation [8, 12, 13, 23-26]. The sensitivity of the patients to radiation in this ‎study was in line with expectations and in line with other studies. Recently, several studies have tried to address the issue of chromosomal sensitivity at the cytogenetic ‎molecular level and the correlation of the outcome (breast cancer disease) with various characteristics ‎such as genetic variations and even polymorphisms [27-29].‎ ‎... [30, 31]. Research results based on new technology in Ukraine are consistent with our research ‎findings regarding the feasibility and applicability of radiation sensitivity testing in the G2 phase of the ‎cell cycle (with X-ray radiation, however) [32]. ... [33-35].‎

The use of the chromosomally sensitive radiation test can be more accurately assessed in cohort ‎studies in the future.



Iranian women with non-inherited breast cancer have more susceptibility to gamma radiation than ‎healthy women, and show this sensitivity as chromosomal breaks and clefts. Therefore, ‎chromosomally sensitive radiation test, have the usability as an early detection of breast cancer ‎biomarker, or a possible indicator of the potentiality of being affected with this disease.

The Genetics Research Center of the University of Rehabilitation Sciences and Welfare is appreciated ‎for financial support. The staff of the Mehrad Hospital are appreciated for their sincere help in taking ‎samples from the patients in optimal condition. Staff members of the Radiation Therapy Center, are ‎thanked and appreciated who helped us to irradiate the samples, and all those who collaborated with ‎us in this project are appreciated as well.





This research was funded by the Genetics Research Center of the University of and Rehabilitation ‎Sciences and Welfare.‎

TABLES and CHARTS

Show attach file


CITIATION LINKS

[1]Dumitrescu RG, Cotarla I. Understanding breast cancer risk -Where do we stand in 2005?. J Cell Mol Med. ‎‎2005;9(1):208-21.‎
[2]Miller A. Causes of breast cancer and high-risk groups. In: Harris JR. Breast Diseases. 2th ed. Philadelphia: JB ‎Lippincott; 1991. p. 119.‎
[3]Santora LM, Mahoney MC, Lawvere S, Englert JJ, Symons AB, Mirand AL. Breast cancer screening beliefs by ‎practice location. BMC Public Health. 2003; 3: 9.‎
[4]Taylor AMR. Chromosome instability syndromes. Clin haematol. 2001;14(3):631-44.‎
[5]Haskell CM. Cancer Treatment. 5th ed. Saunders WB, editor. Philadelphia: W.B. Saunders; 2001.‎
[6]Kahan E, Ibrahim AS, Najjar KE, Ron E, Al-Agha H, Polliack A, et al. Cancer Patterns in the Middle East ‎Special Report from the Middle East Cancer Society. Acta Oncol. 1997;36(6):631-6.‎
[7]Pichierri P, Franchitto A, Palitti F. Predisposition to cancer and radiosensitivity. Genet Mol Biol. ‎‎2000;23(4):1101-5.‎
[8]Smart V, Curwen GB, Whitehouse CA, Edwards A, Tawn EJ. Chromosomal radiosensitivity: A study of the ‎chromosomal G(2) assay in human blood lymphocytes indicating significant inter-individual variability. Mutat ‎Res. 2003;528(1-2):105-10.‎
[9]Bryant PE, Gray L, Riches AC, Steel CM, Finnon P, Howe O, et al. The G2 chromosomal radiosensitivity assay. ‎Int J Radiat Biol. 2002;78(9):863-6.‎
[10]Docherty Z, Georgiou A, Langman C, Kesterton I, Rose S, Camplejohn R, et al. Is chromosome radiosensitivity ‎and apoptotic response to irradiation correlated with cancer susceptibility?. Int J Radiat Biol. 2007;83(1):1-‎‎12.‎
[11]Barwell J, Pangon L, Georgiou A, Kesterton I, Langman C, Arden- Jones A, et al. Lymphocyte radiosensitivity ‎in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer. ‎‎2007;121(7):1631-6.‎
[12]Baeyens A, Thierens H, Claes K, Poppe B, Messiaen L, De Ridder L, et al. Chromosomal radiosensitivity in ‎breast cancer patients with a known or putative genetic predisposition. Br J Cancer. 2002;87(12):1379-85. ‎
[13]Scott D, Barber JB, Spreadborough AR, Burrill W, Roberts SA. Increased chromosomal radiosensitivity in ‎breast cancer patients: A comparison of two assays. Int J Radiat Biol. 1999;75(1):1-10.‎
[14]Barber JB, Burrill W, Spreadborough AR, Levine E, Warrenb C, Kiltie AE, et al. Relationship between in vitro ‎chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage ‎following radiotherapy for breast cancer. Radiother Oncol. 2000;55(2):179-86.‎
[15]Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D. Heritability of cellular ‎radiosensitivity: A marker of low penetrance predisposition genes in breast cancer?. Am J Hum Genet. ‎‎1999;65(3):784-94.‎
[16]Boostma D, Kraemer KH, Cleaver JE, Hoeijmakers JHJ. Nucleotide Excision Repair Syndromes: Xeroderma ‎Pigmentosum, Cockayne Syndrome, and Trichothiodystrophy. In: The Metabolic and Molecular Bases of ‎Inherited Disease. 6th ed. New York: McGraw-Hill; 1989.‎
[17]Cleaver JE. Xeroderma pigmentosum: A human disease in which an initial stage of DNA repair is defective. ‎Proc Natl Acad Sci U S A. 1969;63(2):428-35.‎
[18]Rary JM, Bender MA, Kelly TE. Cytogenetic status of ataxia telangiectasia. Am J Hum Genet. 1974;26:70‎
[19]Sanford KK, Parshad R, Price FM, Jones GM, Tarone RE, Eierman L, et al. Enhanced chromatid damage in ‎blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene. J Natl Cancer Inst. ‎‎1990;82(12):1050-4. ‎
[20]Scott D, Barber JB, Levine EL, Burrill W, Roberts SA. Radiation-induced micronucleus induction in ‎lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: A test for ‎predisposition?. Br J Cancer. 1998;77(4):614-20.‎
[21]Rigaud O, Guedeney G, Duranton I, Leroy A, Doloy MT, Magdelenat H. Genotoxic effects of radiotherapy and ‎chemotherapy on the circulating lymphocytes of breast cancer patients. II. Alteration of DNA repair and ‎chromosome radiosensitivity. Mutat Res. 1990;242(1):25-35.‎
[22]Samouhos E. Chromosomes, cancer and radiosensitivity. Am J Clin Oncol. 1983;6(4):503-6.‎
[23]Riches AC, Bryant PE, Steel CM, Gleig A, Robertson AJ, Preece PE, et al. Chromosomal radiosensitivity in G2- ‎phase lymphocytes identifies breast cancer patients with distinctive tumour characteristics. Br J Cancer. ‎‎2001;85(8):1157–61. ‎
[24]Terzoudi GI, Jung T, Hain J, Vrouvas J, Margaritis K, Donta-Bakoyianni C, et al. Increased G2 chromosomal ‎radiosensitivity in cancer patients: The role of cdk1/cyclin-B activity level in the mechanisms involved. Int J ‎Radiat Biol. 2000;76(5):607-15.‎
[25]Parshad R, Price FM, Bohr VA, Cowans KH, Zujewski JA, Sanford KK. Deficient DNA repair capacity, ‎apredisposing factor in breast cancer. Br J Cancer. 1996;74(1):1–5. ‎
[26]Scott D, Spreadborough A, Levine E, Roberts SA. Genetic predisposition in breast cancer. Lancet. ‎‎1994;344(8934):1444.‎
[27]Abdel-RahmanSZ, El-Zein RA. Evaluating the effects of genetic variants of DNA repair genes using cytogenetic ‎mutagen sensitivity approaches. Biomarkers. 2011;16(5):393-404. ‎
[28]Cadwell KK, Curwen GB, Tawn EJ, Winther JF, Boice JD Jr. G2 checkpoint control and G2 chromosomal ‎radiosensitivity in cancer survivors and their families. Mutagenesis. 2011;26(2):291-4.‎
[29]Kotsopoulos J, Chen Z, Vallis KA, Poll A, Ainsworth P, Narod SA. DNA repair capacity as a possible biomarker ‎of breast cancer risk in female BRCA1 mutation carriers. Br J Cancer. 2007;96(1):118–25.‎
[30]Baria K, Warren C, Roberts SA, West CM, Scott D. Chromosomal radiosensitivity as a marker of predisposition ‎to common cancers?. Br J Cancer. 2001;84(7):892–6.‎
[31]Hill JW, Tansavatdi K, Lockett KL, Allen GO, Takita C, Pollack A, et al. Validation of the cell cycle G(2) delay ‎assay in assessing ionizing radiation sensitivity and breast cancer risk. Cancer Manag Res. 2009;1:39-48.‎
[32]Ryabchenko NM, Glavin OA, Shtefura V, Anikushko MF. Chromosomal radiosensitivity in Ukrainian breast ‎cancer patients and healthy individuals. Exp Oncol. 2012;34(2):121-4.‎
[33]Wilson PF, Nagasawa H, Fitzek MM, Little JB, Bedford JS. G2-phase chromosomal radiosensitivity of primary ‎fibroblasts from hereditary retinoblastoma family members and some apparently normal controls. Radiat ‎Res. 2010;173(1):62-70.‎
[34]Hille A, Hofman-Huther H, Kuhnle E, Wilken B, Rave-Frank M, Schmidberger H, et al. Spontaneous and ‎radiation-induced chromosomal instability and persistence of chromosomeaberrations after radiotherapy in ‎lymphocytes from prostate cancer patients. Radiat Environ Biophys. 2010;49(1):27-37.‎
[35]De Ruyck K, de Gelder V, Van Eijkeren M, Boterberg T, De Neve W, Vral A, et al. Chromosomal radiosensitivity ‎in head and neck cancer patients: Evidence for genetic predisposition?. Br J Cancer. 2008;98(10):1723-38.‎